Generic Yonsa Availability
Last updated on Apr 10, 2025.
Yonsa is a brand name of abiraterone, approved by the FDA in the following formulation(s):
YONSA (abiraterone acetate - tablet;oral)
-
Manufacturer: SUN PHARM
Approval date: May 22, 2018
Strength(s): 125MG [RLD]
Is there a generic version of Yonsa available?
No. There is currently no therapeutically equivalent version of Yonsa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yonsa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Abiraterone steroid formulation
Patent 10,292,990
Issued: May 21, 2019
Inventor(s): Nemeth Paul & Callahan Matt & Bosch H. William & Norret Marck
Assignee(s): SUN PHARMA GLOBAL FZEA nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.
Patent expiration dates:
- May 20, 2034✓
- May 20, 2034
-
Abiraterone acetate formulation and methods of use
Patent 9,889,144
Issued: February 13, 2018
Inventor(s): Murphy Maura & Nemeth Paul & Bosch H. William & Callahan Matthew & Bhamidipati Satya & Coleman Jason & Hill Christopher & Norret Marck
Assignee(s): iCeutica Inc.Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
Patent expiration dates:
- March 17, 2034✓
- March 17, 2034
More about Yonsa (abiraterone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
- Yonsa drug information
- Yonsa (Abiraterone Oral) (Advanced Reading)
- Yonsa (Abiraterone, micronized Oral) (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
